<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526603</url>
  </required_header>
  <id_info>
    <org_study_id>2011OC072</org_study_id>
    <secondary_id>MT2011-11C</secondary_id>
    <nct_id>NCT01526603</nct_id>
  </id_info>
  <brief_title>High Dose Chemotherapy and Autologous Transplant for Neuroblastoma</brief_title>
  <official_title>High Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Rescue for Neuroblastoma: Standard of Care Considerations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a standard of care document, outlining the therapy for children with high risk&#xD;
      neuroblastoma who are not eligible for Children's Oncology Group (COG) studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This therapy involves the use of melphalan, etoposide, and carboplatin (consolidation&#xD;
      chemotherapy); autologous stem cell rescue, post-transplant radiation therapy and a&#xD;
      maintenance phase with Isotretinoin (Accutane, 13-cis-retinoic acid) therapy. If available,&#xD;
      patients should also consider post-transplant therapy with cytokines and monoclonal antibody&#xD;
      (ch14.18) on a COG or New Approaches to Neuroblastoma Therapy (NANT) trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2012</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients with Successful Engraftment</measure>
    <time_frame>Day 42</time_frame>
    <description>The time to neutrophil engraftment will be assessed by standard statistical approaches.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Disease Free Survival</measure>
    <time_frame>2 Years</time_frame>
    <description>The number of patients alive and disease free will be assessed using standard statistical approaches.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 Years</time_frame>
    <description>The number of patients alive will be assessed by standard statistical approaches.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Treatment Related Death</measure>
    <time_frame>1 Year</time_frame>
    <description>The rate of treatment related mortality will be assessed by cumulative incidence approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Disease Free Survival</measure>
    <time_frame>5 Years</time_frame>
    <description>The number of patients alive and disease free will be assessed using standard statistical approaches.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 Years</time_frame>
    <description>The number of patients alive will be assessed by standard statistical approaches.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Patients Treated for Neuroblastoma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>According to patient weight and renal function, consolidation chemotherapy using various doses of Melphalan, Etoposide, and Carboplatin followed by autologous stem cell infusion and serial post-transplant Granulocyte Colony Stimulating Factor, radiation therapy and Isotretinoin maintenance therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin intravenously (IV), 425 mg/m2/dose (or if ≤ 12kg, 14.2 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant.</description>
    <arm_group_label>Patients Treated for Neuroblastoma</arm_group_label>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous stem cell infusion</intervention_name>
    <description>On day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.</description>
    <arm_group_label>Patients Treated for Neuroblastoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Granulocyte colony stimulating factor</intervention_name>
    <description>Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF subcutaneously (SQ) or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir absolute neutrophil count (ANC) &gt; 2000/μL for 3 consecutive days.</description>
    <arm_group_label>Patients Treated for Neuroblastoma</arm_group_label>
    <other_name>G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <description>It is suggested that patients who have a complete surgical resection of the primary tumor receive 21.6 Gy external beam radiation therapy (EBRT) to the post-induction chemotherapy, pre-operative primary tumor volume. It is suggested that patients who have an incomplete surgical resection of the primary tumor (residual soft tissue mass measuring &gt;1 cm3) will receive 21.6 Gy EBRT to the postinduction chemotherapy, pre-operative primary tumor volume and an additional boost of 14.4 Gy EBRT to the gross residual tumor (total dose 36 Gy to gross residual tumor volume). Radiation should be given after stem cell transplantation and should start no sooner than 28 days post transplant.</description>
    <arm_group_label>Patients Treated for Neuroblastoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin (13-cis-retinoic acid)</intervention_name>
    <description>Post-transplant maintenance therapy with cis-RA daily for 14 days every 28 days repeated for 6 months. This phase of the therapy can be initiated by the BMT team and continued by the referring physician. It is recommended to begin Isotretinoin at day 66 post-transplant and no later than day 100. For patients ≤12 kg, isotretinoin (accutane) should be administered at 5.33 mg/kg/dose divided twice daily. For patients &gt;12 kg isotretinoin (accutane) should be administered at 160 mg/m^2/day divided twice a day. Patients should be considered for monoclonal antibody therapy against GD2, such as ch14.18 if such trials are available.</description>
    <arm_group_label>Patients Treated for Neuroblastoma</arm_group_label>
    <other_name>Accutane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan Intravenously (IV), 70 mg/m2/dose (or if ≤ 12 kg, 2.3 mg/kg/dose) once daily x 3 doses on days 7 through 5 pretransplant</description>
    <arm_group_label>Patients Treated for Neuroblastoma</arm_group_label>
    <other_name>Alkeran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide intravenously (IV), 338 mg/m2/dose (or if ≤ 12kg, 11.3 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant</description>
    <arm_group_label>Patients Treated for Neuroblastoma</arm_group_label>
    <other_name>Eposin</other_name>
    <other_name>VP-16</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Less than 30 years of age at diagnosis of neuroblastoma&#xD;
&#xD;
          -  No evidence of disease progression: defined as increase in tumor size of &gt;25% or new&#xD;
             lesions&#xD;
&#xD;
          -  Recovery from last induction course of chemotherapy (absolute neutrophil count &gt; 500&#xD;
             and platelet &gt; 20,000)&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  Minimum frozen peripheral blood stem cells (PBSCs) of 2 x 10^6 CD34 cells/kg for&#xD;
             transplant are mandatory and 2 x 10^6 CD34 cells/kg for back-up are strongly&#xD;
             recommended (thus, PBSC of 4 x 106 CD34 cells/kg is encouraged)&#xD;
&#xD;
          -  Adequate organ function defined as:&#xD;
&#xD;
               -  Hepatic: aspartate aminotransferase (AST) &lt; 3 x upper limit of institutional&#xD;
                  normal 8 Cardiac: shortening fraction ≥ 27% or ejection fraction ≥ 50%, no&#xD;
                  clinical congestive heart failure 8 Renal: Creatinine clearance or glomerular&#xD;
                  filtration rate (GFR) &gt; 60 mL/min/1.73m^2 If a creatinine clearance is performed&#xD;
                  at end induction and the result is &lt; 100 ml/min/1.73m^2, a GFR must then be&#xD;
                  performed using a nuclear blood sampling method or iothalamate clearance method.&#xD;
                  Camera method is NOT allowed as measure of GFR prior to or during Consolidation&#xD;
                  therapy for patients with GFR or creatinine clearance of &lt; 100 ml/min/1.73m^2&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Patients with progressive disease should consider participating in phase I studies&#xD;
             since consolidation therapy using the regimen outlined in this document have not been&#xD;
             determined to be useful.&#xD;
&#xD;
          -  Patients who are delayed in consolidation chemotherapy beyond 8 weeks, and don't meet&#xD;
             organ function criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashish Gupta, MBBS, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Burke</last_name>
    <phone>612-273-8482</phone>
    <email>lburke3@Fairview.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Burke</last_name>
      <phone>612-273-8482</phone>
      <email>lburke3@Fairview.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 31, 2012</study_first_submitted>
  <study_first_submitted_qc>February 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2012</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peripheral blood stem cell transplantation</keyword>
  <keyword>autologous stem cell transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

